The US Food and Drug Administration (FDA) approved Posluma injection on May 25, 2023.

PepGen reports encouraging results from low-dose group in ongoing CONNECT1-EDO51 Phase 2 trial for treating Duchenne Muscular Dystrophy with PGN-EDO51.

durlobactam/sulbactam, marketed under the brand name Xacduro, is FDA approved. The approval was granted on May 23, 2023.

Formycon AG announced the first enrollment in the Phase III "Lotus" study comparing FYB206/pembrolizumab with leading cancer drug Keytruda for safety and efficacy.

Yes, epcoritamab, marketed under the brand name Epkinly, is FDA approved. It received approval on May 19, 2023.

Celldex Therapeutics announces successful findings from Phase 2 trial of Barzolvolimab for chronic inducible urticaria.

Beremagene geperpavec topical, marketed under the brand name Vyjuvek, is an FDA-approved medication for treating wounds caused by dystrophic epidermolysis bullosa (DEB).

Roche disclosed today that the European Commission has given the green light to Vabysmo® (faricimab) .

Perfluorohexyloctane ophthalmic, marketed under the brand name Miebo, is an FDA-approved medication for treating dry eye disease.

Galderma has successfully completed the European decentralized procedure, leading to a favorable decision for RelfydessTM.

Fezolinetant, sold under the brand name Veozah, was approved by the FDA on May 12, 2023.

Compugen has announced that the U.S. Food and Drug Administration has approved the investigational new drug application to begin a Phase 1 trial for COM503.